Tresiba FlexTouch Insulin for Diabetes Pen

Tresiba FlexTouch Insulin Pen – Long-Acting Insulin Degludec for Diabetes Management

Tresiba FlexTouch Insulin Pen contains Insulin Degludec, a long-acting basal insulin used to improve blood glucose control in eligible adults and children with diabetes mellitus. It is supplied as a disposable, pre-filled FlexTouch pen for once-daily subcutaneous administration. Insulin degludec provides prolonged background insulin activity throughout the day and night. It helps lower blood glucose by supporting glucose uptake into muscle and fat cells while reducing excess glucose production by the liver. Tresiba FlexTouch is available in 100 units/ml (U-100) and 200 units/ml (U-200) strengths. Always confirm the exact concentration printed on the pen and use only the dose prescribed by a qualified healthcare professional.

Key Features

• Contains Insulin Degludec: A long-acting basal insulin analogue.
• Pre-Filled FlexTouch Pen: Disposable injection pen designed for subcutaneous administration.
• Two Concentrations: Available as U-100 and U-200 presentations.
• Adjustable Dose Selection: The dose counter displays the number of insulin units to be injected.
• Prescription Treatment: Requires regular blood glucose monitoring and medical supervision.

Active Ingredient

• Insulin Degludec: An ultra-long-acting basal insulin analogue used to support blood glucose control in people with diabetes mellitus.

Available Presentations

• Tresiba FlexTouch U-100: Contains 100 units/ml and 300 units in each 3 ml pen. It delivers 1 to 80 units per injection in one-unit increments.
• Tresiba FlexTouch U-200: Contains 200 units/ml and 600 units in each 3 ml pen. It delivers 2 to 160 units per injection in two-unit increments.
• No dose conversion is required between the two pens because the dose counter displays the actual number of units selected.

Uses

• Improvement of blood glucose control in eligible patients with diabetes mellitus.
• Long-acting basal insulin treatment for type 1 diabetes when used with mealtime insulin.
• Basal insulin treatment for eligible patients with type 2 diabetes.
• Use as part of an individualized treatment plan involving diet, physical activity, and blood glucose monitoring.
• Not recommended for the treatment of diabetic ketoacidosis.

How to Use

• Use Tresiba FlexTouch exactly as prescribed and demonstrated by your healthcare professional.
• Administer it once daily as a subcutaneous injection.
• Inject into the abdomen, thigh, or upper arm.
• Rotate injection sites regularly to reduce the risk of skin thickening, pits, lumps, or localized deposits.
• Check the insulin name, concentration, and selected dose before every injection.
• Use a new compatible sterile pen needle for every injection.
• Perform a flow check before injecting according to the FlexTouch instructions.
• Do not inject Tresiba into a vein or muscle.
• Do not use Tresiba in an insulin-infusion pump.
• Do not mix or dilute Tresiba with another insulin or injectable solution.

Important Administration Instructions

• The solution should appear clear and colourless.
• Do not use it if the solution is cloudy, coloured, thickened, or contains visible particles.
• Do not withdraw insulin from the FlexTouch pen using a syringe.
• Do not perform a concentration or dose conversion when using U-100 or U-200 FlexTouch pens.
• Do not change the insulin strength, dose, or treatment schedule without medical supervision.
• Adults who miss a dose should follow their healthcare provider’s instructions and ensure adequate time between injections.
• Children who miss a dose should receive guidance from their healthcare provider.

Precautions

• Do not use Tresiba during an episode of low blood glucose.
• Monitor blood glucose regularly according to your prescribed diabetes-management plan.
• Inform your doctor if you have kidney disease, liver disease, low potassium levels, heart failure, or recurrent hypoglycaemia.
• Tell your healthcare provider about all insulin products, diabetes medicines, prescription medicines, supplements, and herbal products you use.
• Changes in meals, physical activity, body weight, illness, stress, kidney function, or liver function may change insulin requirements.
• Carry a suitable source of fast-acting glucose as advised by your healthcare professional.
• Do not share the FlexTouch pen or needles with another person, even if the needle has been changed.
• Consult your healthcare provider regarding use during pregnancy or breastfeeding.

Warning

• Hypoglycaemia: Low blood glucose is the most common adverse effect of insulin and may become severe or life-threatening.
• Hyperglycaemia: Missed doses, insufficient insulin, illness, incorrect administration, or treatment changes may cause dangerously high blood glucose.
• Medication Errors: Confusing the U-100 and U-200 pens or using the wrong insulin may cause serious blood glucose complications.
• Allergic Reactions: Seek emergency assistance for facial swelling, breathing difficulty, widespread rash, dizziness, or rapid heartbeat.
• Low Potassium: Insulin may reduce potassium levels in the blood, particularly in susceptible patients.
• Using certain diabetes medicines from the thiazolidinedione class with insulin may cause fluid retention or worsen heart failure.

Common Side Effects

• Low blood glucose.
• Injection-site redness, swelling, itching, or discomfort.
• Skin thickening, pits, lumps, or localized deposits at repeatedly used injection sites.
• Weight gain.
• Swelling caused by fluid retention.
• Skin rash or itching.

Storage

• Store unused Tresiba FlexTouch pens in a refrigerator between 2°C and 8°C.
• Do not freeze or use the pen if it has been frozen.
• Unopened refrigerated pens may be used until the expiry date printed on the packaging.
• An in-use pen may be stored refrigerated between 2°C and 8°C or at room temperature below 30 °C.
• Discard the pen 56 days after first use, even if insulin remains.
• Protect the pen from excessive heat and direct light.
• Store without a needle attached and keep the pen cap in place.
• Keep out of reach of children.

Legal Disclaimer: Tresiba FlexTouch Insulin Pen is a prescription insulin medicine intended for use under the supervision of a qualified healthcare professional. Incorrect insulin selection, dose setting, or administration may cause severe hypoglycaemia or hyperglycaemia. Available strengths and approved age groups may differ by country. This information is provided for educational purposes only and should not replace medical advice, diabetes training, blood glucose monitoring, or the official instructions supplied with the medicine.